Compare
Aytu Biopharma, Inc vs Nektar Therapeutics vs Agios Pharmaceuticals, Inc. vs Q32 Bio Inc.
| Latest fiscal year | Aytu Biopharma, Inc AYTU | Nektar Therapeutics NKTR | Agios Pharmaceuticals, Inc. AGIO | Q32 Bio Inc. QTTB |
|---|---|---|---|---|
| Year ended | 2026-06-30 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $57.57M | $55.23M | $54.03M | $53.74M |
| Revenue growth (YoY) | -13.3% | -43.9% | +48.0% | n/a |
| Gross margin | 64.0% | n/a | 88.3% (computed) | n/a |
| Operating margin | -14.4% | -253.7% | -873.9% | 31.5% |
| Net margin | -24.8% | -297.1% | -764.0% | 55.5% |
| Net income | -$14.25M | -$164.08M | -$412.78M | $29.82M |
| EPS (Diluted) | n/a | -$9.73 | -$7.12 | $2.42 |
| Operating cash flow | $3.28M | -$208.51M | -$372.98M | -$33.54M |
| Free cash flow | $3.25M | -$208.68M | -$377.29M | -$33.54M |
| Cash & equivalents | $26.31M | $15.12M | $89.13M | $48.30M |
| Total assets | $105.01M | $280.41M | $1.30B | $61.78M |
| Total liabilities | n/a | $190.57M | $104.11M | $19.76M |
| Shareholders' equity | $35.27M | $89.83M | $1.19B | $42.01M |
| Return on year-end equity | -40.4% | -182.6% | -34.6% | 71.0% |
| Shares outstanding | 10.73M | 20.38M | 58.45M | 12.86M |
Revenue, most recent five fiscal years
| Fiscal year | Aytu Biopharma, Inc | Nektar Therapeutics | Agios Pharmaceuticals, Inc. | Q32 Bio Inc. |
|---|---|---|---|---|
| Latest | $57.57M Ended 2026-06-30 | $55.23M Ended 2025-12-31 | $54.03M Ended 2025-12-31 | $53.74M Ended 2025-12-31 |
| 1 year earlier | $66.38M Ended 2025-06-30 | $98.43M Ended 2024-12-31 | $36.50M Ended 2024-12-31 | $0 Ended 2024-12-31 |
| 2 years earlier | $65.18M Ended 2024-06-30 | $90.12M Ended 2023-12-31 | $26.82M Ended 2023-12-31 | -$6.65M Ended 2023-12-31 |
| 3 years earlier | $107.40M Ended 2023-06-30 | $92.06M Ended 2022-12-31 | $14.24M Ended 2022-12-31 | n/a |
| 4 years earlier | $96.67M Ended 2022-06-30 | $101.91M Ended 2021-12-31 | $0 Ended 2021-12-31 | n/a |